lafutidine lafutidine lafutidine (inn) is a second generation histamine h2 receptor antagonist having multimodal mechanism of action and used to treat gastrointestinal disorders. it is marketed in south korea, japan and india. lafutidineclinical dataahfs/drugs.cominternational drug namesroutes ofadministrationoralatc codea02ba08 (who) identifiers iupac name 2-(furan-2-ylmethylsulfinyl)-n-oxybut-2-enyl]acetamide cas number206449-93-6 ypubchem cid5282136chemspider4445337 nunii49s4o7adlckeggd01131 ycomptox dashboard (epa)dtxsid0046434 echa infocard100.118.935 chemical and physical dataformulac22h29n3o4smolar mass431.55 g·mol−13d model (jsmol)interactive image smiles c1ccccn1cc2ccnc(c2)oc/c=c\cnc(=o)cs(=o)cc3ccco3 inchi inchi=1s/c22h29n3o4s/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15h,1,3-4,9,11-13,16-18h2,(h,23,26)/b5-2- nkey:kmzqavxsmukbpd-djwkrkhssa-n n ny (what is this?) (verify) medical use lafutidine is used to treat gastric ulcers, duodenal ulcers, as well as wounds in the lining of the stomach associated with acute gastritis and acute exacerbation of chronic gastritis. adverse effects adverse events observed during clinical trials included constipation, diarrhea, drug rash, nausea, vomiting and dizziness. mechanism of action like other h2 receptor antagonists, lafutidine acts by preventing the secretion of gastric acid. it also activates calcitonin gene-related peptide, resulting in the stimulation of nitric oxide (no) and regulation of gastric mucosal blood flow, increases somatostatin levels also resulting in less gastric acid secretion, causes the stomach lining to generate more mucin, inhibits neutrophil activation thus preventing injury from inflammation, and blocks the attachment of helicobacter pylori to gastric cells. trade names it is marketed in japan as stogar by ucb and in india as lafaxid by zuventus healthcare. it is also marketed in south korea as ildong lafutidine by ildong pharmaceutical co ltd.